BiotechTube
GeneType

GeneType

San Francisco, United States· Est.
genetype.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

GeneType, founded in 2017 and headquartered in San Francisco, is a leader in the personalized predictive genetics space. Its core offering is the geneType platform, which combines polygenic risk scores, inherited monogenic data, and clinical risk factors into integrated risk assessments for a range of chronic diseases. The company's flagship Multi-Risk Test (MRT), launched in 2021, has demonstrated significant clinical utility, identifying a high percentage of at-risk individuals without a family history. GeneType operates a B2B2C model, distributing its tests exclusively through medical practitioners, and is backed by over 20 years of scientific research, numerous patents, and peer-reviewed publications.

OncologyCardiovascular DiseaseMetabolic Disease

Technology Platform

Integrated risk assessment platform combining Polygenic Risk Scores (PRS), inherited monogenic (germline) data, and clinical risk factors to predict an individual's likelihood of developing chronic diseases.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing emphasis on preventative healthcare and value-based care models creates a massive opportunity for proactive risk assessment tools.
GeneType can capitalize on this by expanding partnerships with healthcare systems and employers focused on reducing long-term costs.
Furthermore, the platform's ability to identify at-risk individuals without a family history opens up a vast, underserved market segment.

Risk Factors

Key risks include navigating an uncertain regulatory environment for genetic tests and securing insurance reimbursement, which is critical for adoption.
The company also faces competition from larger, established players and must continuously prove the clinical utility and real-world impact of its polygenic risk scores to gain trust from the medical community.

Competitive Landscape

GeneType competes in the crowded direct-to-consumer and clinician-ordered genetic testing market. Key competitors include companies like 23andMe (for health predisposition), Myriad Genetics (for hereditary cancer), and other specialized polygenic risk score companies (e.g., Allelica, Genomics PLC). GeneType's differentiation lies in its integrated model that combines PRS, monogenic, and clinical risk into a single, clinically actionable report.

More companies in Diagnostics & Precision Medicine →More companies in United States →